# Zinc L-carnosine: gastric mucosa, Hsp70 and the evidence

- Canonical: https://nutrifit.health/knowledge/zinc-l-carnosine-gastric-mucosal-healing-hsp70
- Language: en
- Published: 2026-10-09T00:25:42.399Z
- Updated: 2026-10-09T00:25:42.399Z
- Author: NutriFit Editorial

> How polaprezinc relates to gastric retention, Hsp70 and the intestinal barrier; what aspirin, exercise, H. pylori and mucositis trials actually showed, with elemental zinc calculations and copper risks.

Zinc L-carnosine, also called polaprezinc, is a coordination complex of zinc and the dipeptide L-carnosine. Researchers study it as a mucosal protective agent, and a pharmaceutical formulation is approved in Japan for gastric ulcer. Interest comes from a combination of local gastric retention, cellular stress responses and the roles of zinc in epithelial biology. These properties do not establish a general treatment for gastritis, reflux, intestinal permeability or *Helicobacter pylori* infection.

Three questions help organize the evidence. Can a substance alter a molecular process? Can it improve a measured experimental endpoint? Does it improve a patient's condition in a specified disease and treatment setting? The answers for polaprezinc come from different experiments. An increase in Hsp70 in cultured cells, a change in the urinary ratio of two sugars and prevention of clinically important bleeding are distinct outcomes.

## The complex, free zinc and carnosine

Carnosine consists of β-alanine and L-histidine. Histidine's imidazole ring and other donor groups enable metal binding. Polaprezinc contains zinc and carnosine in a 1:1 ratio; the solid is described as a polymeric coordination complex, including in the spectroscopic work of Wagner and Baran (2008). Chelation describes a chemical form. It does not prove superior efficacy for every product carrying a similar name.

The complex has the empirical formula C₉H₁₂N₄O₃Zn and a molar mass of about 289.61 g/mol. The solid structure, dissolution in an acidic environment and the chemical form of zinc after absorption are different issues. One cannot assume that the entire swallowed complex crosses the mucosa unchanged and selectively delivers zinc to every ulcer. A simple mixture of a zinc salt and carnosine does not automatically reproduce the original formulation either: complex formation, particle size, solubility, dose and route matter.

Chemical differences also do not mean that free zinc salts can never be protective. In primary mouse hepatocytes, Nishida and colleagues (2010) found that both polaprezinc and zinc sulfate induced Hsp70 and reduced acetaminophen toxicity; carnosine alone did not produce that result. This is a counterexample to the claim that only an intact zinc–carnosine complex can raise Hsp70. It concerns a particular cell model, not treatment of human liver injury.

## What local retention means

Furuta and colleagues (1995) tracked ¹⁴C- and ⁶⁵Zn-labelled components in rats. The mean residence time of polaprezinc in the stomach was approximately two hours, about twice that of free carnosine or zinc sulfate. The area under the gastric tissue radioactivity curve over 0–8 hours was approximately 1.7 times higher. Retention at ulcerated sites exceeded that of polaprezinc that had first been dissolved in acid.

This experiment supports contact with a damaged surface. It does not establish a fixed six-hour coating in humans, a tenfold ulcer concentration or superiority over a proton pump inhibitor. A radiolabel tracks labelled components; its detection alone does not establish that the original coordination structure remains intact. Gastric emptying, food, acidity and formulation can all change exposure.

Polaprezinc does not suppress acid secretion in the same way as a proton pump inhibitor. Nor is it equivalent to sucralfate: a shared aim of mucosal protection does not mean identical binding, coating composition or indications. Comparing agents requires direct trials in the same disease using comparable outcomes.

[![Local polaprezinc retention, conceptual Hsp70/Hsp72 protein protection and epithelial migration in cell and animal models.](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-zinc-l-carnosine-gastric-mucosal-healing-hsp70-mucosal-defense-en-v1.png)](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-zinc-l-carnosine-gastric-mucosal-healing-hsp70-mucosal-defense-en-v1.png)

*The diagram connects three research levels: local retention near damaged mucosa, a cellular stress response and epithelial restitution. Complex particles and the chaperone icon are conceptual; they do not depict atomic structure or direct binding of polaprezinc to Hsp70. These mechanisms do not establish human ulcer healing.*

## Hsp70: a causal link within a model

Heat shock proteins support proteostasis: the production, repair and disposal of proteins. The Hsp70 family includes constitutive and inducible forms; Hsp72 is commonly used for an inducible member. Chaperone activity involves cycles of ATP binding and hydrolysis. Hsp70 is neither an acid-neutralizing enzyme nor an antibiotic. Hsp27 has other stress-response functions; a finding for one protein cannot simply be extended to Hsp60 or the entire heat shock system.

Qin and colleagues (2011) pretreated rat intestinal epithelial RIE-1 cells with 70 µmol/L polaprezinc for 24 hours, then exposed them to 15 mmol/L acetylsalicylic acid for 15 hours. Reduced late apoptosis accompanied increased Hsp70. Silencing Hsp70 with specific siRNA abolished the observed protection. This intervention is more informative than two correlated measurements: it identifies a necessary component of protection in that experimental setting.

Cell-culture concentrations are not patient doses. RIE-1 cells do not reproduce blood flow, neural regulation, the immune system or the full course of ulcer disease. The experiment does not establish a single exclusive mechanism or obligatory phosphorylation of a particular HSF1 residue in humans. Precise claims about HSF1, Ser326 and downstream signalling require their own direct evidence.

Ohkawara and colleagues (2006) exposed human-derived Caco-2 cells to hydrogen peroxide. Polaprezinc increased Hsp27 and Hsp72 and reduced oxidative injury; quercetin weakened those effects. This supports involvement of stress proteins, but quercetin is not a perfectly selective Hsp switch. Even a human-derived cell line cannot confirm treatment of ulcerative colitis in patients. The authors noted that the upstream mechanism of Hsp induction was not fully understood.

## Oxidative stress and cell death

Zinc does not behave like iron in the Fenton reaction and does not replace the antioxidant network. In Cu/Zn superoxide dismutase, SOD1, zinc mainly supports structure while copper participates in the catalytic cycle. Mitochondrial SOD2 uses manganese. Increasing dietary zinc does not imply a proportional increase in either enzyme's activity.

Superoxide dismutase converts superoxide to hydrogen peroxide. Subsequent peroxide removal depends on catalase, glutathione peroxidases and other systems. That sequence explains why a reduction in one oxidation marker cannot be called complete restoration of redox balance. Compartments and reaction kinetics are discussed in the article on [catalase, peroxisomes and hydrogen peroxide](/knowledge/catalase-peroxisomes-hydrogen-peroxide-kinetics).

Carnosine, zinc availability, stress proteins, inflammatory signals and membrane preservation can all contribute to experimental protection. Heat-stressed intestinal cell experiments have also examined the Bcl-2/Bax balance and caspase-3 and -9 activity. Bcl-2 and Bax participate in the mitochondrial apoptosis pathway; caspases reflect later steps of cell death. Preserving a cell in such an experiment does not prove that polaprezinc is beneficial in every inflammatory, fibrotic or malignant condition.

Another verified component is heme oxygenase-1, HO-1. This enzyme participates in heme breakdown, producing biliverdin, carbon monoxide and released iron; its effects depend on context and subsequent iron handling. Ueda and colleagues (2009) found dose-dependent HO-1 induction in rat gastric mucosa. An HO-1 inhibitor weakened polaprezinc's protection against acute acid injury. This supports an experimental mechanism, not a human treatment claim. HO-1 induction alone also does not establish an obligatory Nrf2→HO-1 pathway in every tissue and at every dose.

## Restitution, circulation and the quality of healing

Restitution is early closure of a superficial epithelial defect through migration of surviving cells. Each cell does not first have to divide. Restoration of glandular architecture, vessels and extracellular matrix occurs on another timescale. Cell migration, a smaller erosion and freedom from relapse a year later are therefore not interchangeable.

Mahmood and colleagues (2007) combined experimental approaches to intestinal repair with a small study in ten healthy volunteers exposed to indomethacin. The work supports further investigation of barrier protection. It does not supply a universal prevention protocol for complications of every nonsteroidal anti-inflammatory drug.

Complete healing depends on perfusion, angiogenesis, growth factors and balanced matrix turnover. VEGF, EGF, bFGF, matrix metalloproteinases and their tissue inhibitors are biologically relevant research directions. The existence of these pathways does not establish a particular clinical effect of polaprezinc. Claims of restored eNOS signalling through Ser1177, preserved endothelial glycocalyx, obligatory MMP-9 suppression or superior scar quality need direct evidence in the relevant tissue and disease. Endoscopic closure alone also does not demonstrate fewer future relapses.

## The intestinal barrier: structure and measurement

Claudins and occludin are components of tight junctions between cells; ZO-1 links junctional complexes to the intracellular scaffold. Permeability depends on epithelial type, junction composition, inflammation, blood flow and transport through cells themselves. Mucus and local immune defenses provide additional layers. The relationship between junctions and the movement of bacterial products is explained in the article on [intestinal permeability, zonulin, claudins and LPS translocation](/knowledge/intestinal-permeability-zonulin-claudins-lps-translocation).

The gastric mucin layer is also heterogeneous. MUC5AC is associated mainly with surface foveolar cells, whereas MUC6 is produced by neck and gland cells. Ho and colleagues (2004) mapped their spatial distribution in histologically normal surgical tissue specimens. This helps explain why more mucus does not necessarily restore all of its components. That study did not test polaprezinc and cannot support selective increases in MUC5AC or MUC6 caused by the agent.

Where three cells meet, a specialized junctional region forms. The membrane protein tricellulin contributes to sealing it. In the primary study by Ikenouchi and colleagues (2005), RNA-interference suppression of tricellulin compromised the epithelial barrier. This finding explains junctional biology; it does not establish that polaprezinc increases tricellulin or restores such contacts in patients. The diagram below deliberately shows a general apical junction without atomic protein architecture.

In cultured cells, transepithelial electrical resistance, TEER, measures resistance to ion movement across a layer. Investigators may compare it with passage of a separate tracer such as horseradish peroxidase. TEER and tracer transport assess different properties; one cannot substitute for the other.

Human permeability studies can use sugars. After known doses of lactulose and rhamnose, their urinary recovery is measured over a specified interval. The L/R ratio compares recovered fractions of the administered doses, rather than any two arbitrary concentrations:

$$
R_{L/R}=\frac{u_L/d_L}{u_R/d_R}.
$$

Here $u_L$ and $u_R$ are the amounts of each sugar recovered in urine; $d_L$ and $d_R$ are the administered amounts in the same units. The ratio is dimensionless. Protocol, collection time, absorption and renal excretion affect it. It does not directly measure LPS entering the bloodstream, and different laboratory protocols do not automatically share a diagnostic threshold across diseases.

[![Apical tight junction, conceptual urinary L/R workflow and a separate cell-culture TEER measurement.](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-zinc-l-carnosine-gastric-mucosal-healing-hsp70-barrier-measurement-en-v2.png)](https://api.nutrifit.health/api/v2/public/knowledge/files/images/nutrifit-scientific-20261002-zinc-l-carnosine-gastric-mucosal-healing-hsp70-barrier-measurement-en-v2.png)

*Junctions and sample collection are shown conceptually. Blue pentagons represent lactulose and red circles represent rhamnose; these are schematic glyphs, not molecular structures. The aggregate arrow does not claim an identical transport route for both sugars. Urinary L/R requires normalization to the administered dose of each sugar. TEER refers to electrical resistance across a cell layer in vitro. Neither surrogate alone establishes prevention of bleeding or treatment of an inflammatory disease.*

## Exercise: what an eight-person experiment showed

Davison and colleagues (2016) studied eight healthy, physically active men in a crossover trial. Each received four conditions: placebo, zinc carnosine, bovine colostrum and the combination. Treatment periods lasted 14 days, separated by 14-day washouts. Zinc carnosine was given at 37.5 mg twice daily, a total of 75 mg of the compound per day. Colostrum was given at 10 g twice daily.

After 20 minutes of running at 80% of maximal oxygen uptake, the placebo condition produced an approximately threefold rise in L/R. On day 14, the exercise-induced rise was attenuated by 71% with zinc carnosine, 68% with colostrum and 85% with the combination. These percentages describe attenuation of a challenge-induced change, not the proportion of patients whose intestines were healed. The combination's advantage over zinc carnosine alone did not reach the conventional significance threshold: p=0.069. Supplementation did not lower core temperature.

On day two, the individual agents did not yet have a significant effect, while the combination attenuated the rise by approximately 30%. A separate part of the study used cultured cells heated from 37 to 39 °C. It examined Hsp70, apoptosis and junctional proteins. Changes in ZO-1 phosphorylation cannot be reported as a universal increase in total ZO-1: total amounts were not altered by the test factors.

The small sample, male participants without disease and laboratory exercise limit generalization. The study does not establish prevention of heat stroke, sepsis or gastrointestinal bleeding, or efficacy in athletes with chronic symptoms. Hydration, intensity, food tolerance and environmental conditions also matter during competition.

## Aspirin and the small bowel: a capsule-endoscopy pilot

Watari and colleagues (2013) enrolled 20 patients taking long-term low-dose aspirin who had lesions on capsule endoscopy. Ten received polaprezinc 150 mg/day for four weeks; ten served as controls. In the treatment group the median number of erosions and ulcers declined from 2 to 0, with a within-group p value of 0.039. Reddened areas also decreased.

The crucial limitation is often lost in summaries: changes in the overall capsule-endoscopy score did not differ significantly between groups. A significant change in one group and a nonsignificant change in another do not establish a significant difference in treatment effects. A small pilot helps design a subsequent study but does not establish fewer major bleeds.

The result cannot simply be extended to all NSAIDs, direct oral anticoagulants or antithrombotic combinations. Gastric protection and small-bowel protection also require different endpoints. Decisions about protection during prescribed aspirin therapy depend on patient risk and standard care. Interest in a supplement is not a reason to stop a prescribed antithrombotic drug.

## Helicobacter pylori: an adjunct to a regimen

*H. pylori* urease contains nickel and converts urea to ammonia and carbon dioxide. Its contribution to survival in acid explains interest in metal interactions. Yet zinc-related changes in an enzyme experiment do not demonstrate reliable displacement of nickel from bacterial urease by oral polaprezinc in patients. CagA/VacA virulence, biofilms and antibiotic-resistance mutations are separate questions. Mucosal protection does not automatically overcome them.

Urease catalyses this overall reaction:

$$
\mathrm{CO(NH_2)_2}+\mathrm{H_2O}\longrightarrow2\,\mathrm{NH_3}+\mathrm{CO_2}.
$$

Ammonia binds protons to form ammonium, helping raise local pH. This chemistry does not establish clinical antibacterial efficacy of the complex.

In the open-label multicentre Chinese trial by Tan and colleagues (2017), 332 patients with *H. pylori*-associated gastritis were randomized to 14 days of omeprazole, amoxicillin and clarithromycin, with either of two polaprezinc doses or without polaprezinc.

| Addition to the same triple regimen | Randomized | Eradication in the ITT analysis |
|---|---:|---:|
| Polaprezinc 75 mg twice daily | 113 | 77.0% |
| Polaprezinc 150 mg twice daily | 108 | 75.9% |
| No polaprezinc | 111 | 58.6% |

For the first dose, the absolute difference was 18.4 percentage points. Doubling the dose did not improve eradication. Recorded adverse-event frequencies were 2.8%, 5.1% and 1.9%, respectively, which does not establish a general reduction in antibiotic side effects. The trial was open-label, manufacturer-funded and retrospectively registered. The low success of the control clarithromycin regimen is central to interpretation.

Modern eradication choices depend on resistance, previous antibiotic exposure and region. The official ACG 2024 guideline summary recommends 14-day optimized bismuth quadruple therapy as a major option and restricts empiric clarithromycin triple therapy when susceptibility is unknown. Maastricht VI also frames treatment around resistance and effective combinations. This polaprezinc trial does not make the agent a required component of every current regimen, including vonoprazan-based treatment.

Eradication must be confirmed with an appropriate test. ACG specifies at least four weeks after antibiotics and two weeks off proton pump inhibitors or potassium-competitive acid blockers before testing. Coordinating these intervals with the treating clinician matters more than replacing prescribed medicines with a supplement. Improved pain does not confirm that the organism has disappeared.

## Ulcer disease, reflux and functional symptoms

The Japanese PROMAC label specifies gastric ulcer as the indication and a usual adult regimen of 75 mg twice daily, with individual adjustment. Approval of one pharmaceutical formulation in one country does not automatically apply to another manufacturer's supplement. The labelled dose refers to the compound, not elemental zinc.

Ulcer care must address the cause: *H. pylori*, an injurious medicine or another factor. Endoscopic closure, pain relief, glandular restoration and prevention of recurrence are assessed separately. Polaprezinc cannot be credited with proven relapse reduction relative to a proton pump inhibitor without an appropriate direct comparison. Nor is reversal of atrophy, intestinal metaplasia or OLGA stage established, and the agent does not replace investigation of a suspicious lesion.

Reflux depends on movement of gastric contents into the oesophagus as well as mucosal resistance. Functional dyspepsia and irritable bowel syndrome have their own diagnostic criteria and mechanisms, including sensitivity and motility. Extending an ulcer model to these disorders, 5-HT regulation or microbiome restoration remains a hypothesis without direct clinical studies of the relevant outcome. A change in one microbial taxon does not demonstrate restoration of an entire ecosystem.

## Colitis and mucositis: route changes the question

Itagaki and colleagues (2014) studied 28 patients with active ulcerative colitis. Eighteen received a 150 mg polaprezinc enema and ten received control treatment; all continued usual induction therapy. After one week, clinical response or remission was recorded in 71% versus 10%. This was the combined outcome of response or remission, not 71% complete endoscopic remission. Small, unequal groups, short follow-up and adjunctive treatment limit the conclusion. Rectal exposure is not equivalent to a swallowed capsule and does not provide a home enema recipe.

Oral mucositis during cancer treatment has been studied separately. In ToPaZ, Nakagaki and colleagues (2024) randomized 108 patients undergoing haematopoietic stem cell transplantation to topical polaprezinc or sodium bicarbonate mouthwash. Severe WHO grade 3–4 mucositis occurred in 35% and 36%, respectively; secondary outcomes also did not differ. This negative result prevents a promise of severe mucositis prevention based solely on Hsp mechanisms.

Indication, route and comparator matter. A topical trial does not automatically disprove every formulation, but early positive work also does not validate all subsequent cancer applications. Taste recovery, radiation proctitis, caustic injuries in children, liver injury and fibrosis prevention each require their own studies. A hepatocyte experiment or a short colitis trial cannot replace them.

## Elemental zinc: calculation, transport and copper

Pure complex contains approximately 22.6% zinc by mass:

$$
m_{Zn}=m_{\text{complex}}\times\frac{65.38}{289.61}\approx0.226\,m_{\text{complex}}.
$$

Masses must use the same units; 65.38 g/mol is zinc's atomic mass. Therefore 75 mg of complex supplies approximately 16.9 mg elemental zinc, 150 mg supplies 33.9 mg, and 300 mg supplies 67.7 mg. Check the actual composition and label: “zinc 15 mg as zinc carnosine” may already state the elemental amount. Adding the calculated fraction again would double-count it.

Released zinc enters ordinary zinc transport and homeostasis. ZIP4 is involved in intestinal uptake, ZnT1 in cellular export, and metallothionein binds metals inside cells. Zinc status regulates these processes. Formulation does not abolish homeostasis. A transporter variant without a clinically validated dosing rule cannot determine a personalized polaprezinc dose.

Excess zinc promotes copper retention in intestinal cells and can reduce copper availability to the body. NIH ODS notes that 50 mg or more of elemental zinc daily for several weeks can interfere with copper absorption. Consequences include anaemia and neurological injury; the risk does not begin only after a fixed three or six months. The Japanese label lists copper deficiency, including anaemia and pancytopenia in malnourished patients, as a serious adverse reaction of unknown frequency.

The US tolerable upper intake level for healthy adults is 40 mg elemental zinc daily from all sources. It is not a universal ceiling for medically supervised treatment, but it helps distinguish routine supplementation from therapy. Food, multivitamins, cold remedies and other supplements contribute to total intake. Automatically adding copper at a universal ratio is not a substitute for assessing the reason, duration and need for zinc treatment.

## Tolerability, interactions and product selection

The polaprezinc label lists nausea, constipation, abdominal distension and other gastrointestinal reactions, changes in liver tests and serious reactions of unknown frequency including liver injury and jaundice. An absence of major problems in a small trial does not mean an absence of risk. The label states that paediatric clinical trials of that pharmaceutical formulation have not been conducted; pregnancy and breastfeeding require a separate benefit–risk assessment.

Zinc binds some medicines. For tetracyclines and quinolones, NIH ODS advises taking the antibiotic at least two hours before zinc or four to six hours after it; penicillamine should be separated by at least an hour. These intervals concern specified drugs, not every tablet. The particular medicine's instructions and the patient's prescribed schedule take precedence.

Check the chemical form, compound and elemental zinc amounts, excipients and regulatory status on the package. Spectroscopy and diffraction can characterize raw material, but an arbitrary list of FTIR bands or XRD peaks is not a universal certificate of clinical equivalence. An ingredient mixture, a patent for a sustained-release hydrogel and an approved medicine are different objects. Laboratory release time does not establish mucosal healing.

Combinations with colostrum, deglycyrrhizinated licorice or mastic require evidence for the actual combination. Even the colostrum experiment does not establish benefits for every combined supplement. Black stools, vomiting blood, progressive weakness, difficulty swallowing or persistent weight loss require medical assessment; trying a mucosal supplement does not resolve the diagnostic question.

## Reading the next study

Polaprezinc has a coherent experimental research line: local retention, stress proteins, cell preservation and changes in barrier measurements. Its useful continuation is trials with a clearly defined population, formulation, elemental zinc dose, comparator and clinical endpoint. Randomization, blinding, completion of follow-up and analysis of all randomized patients affect confidence in a result.

A positive Hsp70 or L/R change answers a limited question. A between-group difference in healing, symptoms, bleeding or confirmed eradication answers another. Recognizing the distinction allows a precise discussion of polaprezinc as a particular researched or prescribed agent while retaining interest in its biology.

## Sources and review limits

Prepared on 8 October 2026 using selected primary publications and official prescribing information and guidance. Verification used available full texts, primary abstracts and bibliographic records; some publisher, PubMed and PMC pages were inaccessible through the research tool. Unverified precise effects and treatment protocols were not carried into the article. This is an editorial narrative review, not a systematic review, GRADE assessment or external peer review. Available evidence and its limits are stated alongside each study.

## FAQ

### Are polaprezinc and zinc L-carnosine the same?

Polaprezinc names the zinc–L-carnosine complex. This does not establish equivalence of every supplement; chemical form, composition, dose and route still matter.

### Can it replace H. pylori eradication therapy?

No. A trial studied addition to a particular antibiotic regimen. Choosing effective current treatment and confirming eradication remain separate tasks.

### Does increased Hsp70 prove ulcer healing?

No. It indicates a cellular stress response. Clinical studies of healing and recurrence are needed for those outcomes.

### Does 150 mg of the complex mean 150 mg zinc?

No. Pure complex provides approximately 33.9 mg elemental zinc. A label may already list the elemental amount.

### Can enema results be applied to capsules?

No. Rectal exposure, topical mouthwash and a swallowed capsule have different exposure profiles and require separate evaluation.

### What does the L/R test measure?

It describes urinary recovery of two sugars after specified doses under a particular protocol. It is not a direct blood LPS test or proof of a clinical complication.

## Sources

- [Wagner CC, Baran EJ. Vibrational spectra of polaprezinc, a polymeric Zn(II) complex of carnosine. Journal of Raman Spectroscopy. 2008;39:474–477.](https://doi.org/10.1002/jrs.1861)
- [Furuta S et al. Residence Time of Polaprezinc (Zinc L-Carnosine Complex) in the Rat Stomach and Adhesiveness to Ulcerous Sites. Japanese Journal of Pharmacology. 1995;67:271–278.](https://www.jstage.jst.go.jp/article/jphs1951/67/4/67_4_271/_article/-char/en)
- [Qin Y et al. Heat shock protein 70-dependent protective effect of polaprezinc on acetylsalicylic acid-induced apoptosis of rat intestinal epithelial cells. Journal of Clinical Biochemistry and Nutrition. 2011;49:174–181.](https://www.jstage.jst.go.jp/article/jcbn/49/3/49_11-26/_article)
- [Ohkawara T et al. Polaprezinc protects human colon cells from oxidative injury induced by hydrogen peroxide: Relevant to cytoprotective heat shock proteins. World Journal of Gastroenterology. 2006;12:6178–6181.](https://www.wjgnet.com/1007-9327/full/v12/i38/6178.htm)
- [Nishida T et al. Zinc Supplementation with Polaprezinc Protects Mouse Hepatocytes against Acetaminophen-Induced Toxicity via Induction of Heat Shock Protein 70. Journal of Clinical Biochemistry and Nutrition. 2010;46:43–51.](https://www.jstage.jst.go.jp/article/jcbn/46/1/46_09-60/_article)
- [Mahmood A et al. Zinc carnosine, a health food supplement that stabilises small bowel integrity and stimulates gut repair processes. Gut. 2007;56:168–175.](https://doi.org/10.1136/gut.2006.099929)
- [Davison G et al. Zinc carnosine works with bovine colostrum in truncating heavy exercise-induced increase in gut permeability in healthy volunteers. American Journal of Clinical Nutrition. 2016;104:526–536.](https://kar.kent.ac.uk/id/document/48643)
- [Watari I et al. Effectiveness of polaprezinc for low-dose aspirin-induced small-bowel mucosal injuries as evaluated by capsule endoscopy: a pilot randomized controlled study. BMC Gastroenterology. 2013;13:108.](https://link.springer.com/article/10.1186/1471-230X-13-108)
- [Itagaki M et al. Efficacy of zinc–carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis. Scandinavian Journal of Gastroenterology. 2014;49:164–172.](https://pubmed.ncbi.nlm.nih.gov/24286534/)
- [Tan B et al. Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial. PLOS ONE. 2017;12:e0175625.](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0175625)
- [Nakagaki M et al. A randomised trial of topical polaprezinc to prevent oral mucositis in patients undergoing haematopoietic stem cell transplantation (ToPaZ study). Supportive Care in Cancer. 2024;32:44.](https://link.springer.com/article/10.1007/s00520-023-08235-y)
- [PROMAC D Tablets 75 (polaprezinc). Japanese electronic prescribing information. PMDA / Zeria Pharmaceutical; revision 2023.](https://www.pmda.go.jp/PmdaSearch/bookSearch/01/14987103011634)
- [NIH Office of Dietary Supplements. Zinc: Fact Sheet for Health Professionals. Elemental zinc, upper intake levels, copper deficiency and medicine interactions.](https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/)
- [Malfertheiner P et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71:1724–1762.](https://doi.org/10.1136/gutjnl-2022-327745)
- [American College of Gastroenterology / Schoenfeld P. ACG Guideline on Treatment of Helicobacter pylori: New Recommendations… Will Practice Change? Official guideline summary. September 2024.](https://gi.org/journals-publications/ebgi/schoenfeld_sep2024/)
- [Ueda K et al. Polaprezinc (Zinc L-Carnosine) Is a Potent Inducer of Anti-oxidative Stress Enzyme, Heme Oxygenase (HO)-1 — a New Mechanism of Gastric Mucosal Protection. Journal of Pharmacological Sciences. 2009;110:285–294.](https://www.jstage.jst.go.jp/article/jphs/110/3/110_09056FP/_article/-char/en)
- [Ho SB et al. The Adherent Gastric Mucous Layer Is Composed of Alternating Layers of MUC5AC and MUC6 Mucin Proteins. Digestive Diseases and Sciences. 2004;49:1598–1606.](https://link.springer.com/article/10.1023/B:DDAS.0000043371.12671.98)
- [Ikenouchi J et al. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. Journal of Cell Biology. 2005;171:939–945.](https://rupress.org/jcb/article-abstract/171/6/939/52103/Tricellulin-constitutes-a-novel-barrier-at)